Stephen S Whitehead

List of Publications by Year in Descending Order

32 papers	2,044 citations	21 h-index	33 g-index
33 ext. papers	2,450 ext. citations	10.9 avg, IF	4.4 L-index

#	Paper	IF	Citations
32	Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand.. *PLoS Pathogens*, **2022**, 18, e1010500	7.6	0
31	Antigenic evolution of dengue viruses over 20 years. *Science*, **2021**, 374, 999-1004	33.3	5
30	Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model. *Nature Communications*, **2021**, 12, 3054	17.4	5
29	A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. *Nature Communications*, **2021**, 12, 1102	17.4	12
28	Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. *Cell Reports*, **2020**, 33, 108226	10.6	13
27	Nonhuman primates exposed to Zika virus in utero are not protected against reinfection at 1 year postpartum. *Science Translational Medicine*, **2020**, 12,	17.5	1
26	Rapid Induction and Maintenance of Virus-Specific CD8 T and CD4 T Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans. *Frontiers in Immunology*, **2020**, 11, 479	8.4	12
25	Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. *Journal of Infectious Diseases*, **2019**, 220, 219-227	7	15
24	Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model. *EBioMedicine*, **2019**, 41, 465-478	8.8	13
23	Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. *Nature Communications*, **2018**, 9, 1624	17.4	50
22	Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers. *Journal of Infectious Diseases*, **2018**, 218, 1911-1921	7	6
21	Routes of Zika virus dissemination in the testis and epididymis of immunodeficient mice. *Nature Communications*, **2018**, 9, 5350	17.4	21
20	Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. *PLoS Neglected Tropical Diseases*, **2018**, 12, e0006862	4.8	52
19	Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. *Cell Reports*, **2018**, 25, 1214-1224	10.6	27
18	Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. *Journal of Virology*, **2017**, 91,	6.6	16
17	Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. *Journal of Virology*, **2017**, 91,	6.6	37
16	Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. *Journal of Virology*, **2017**, 91,	6.6	59

List of Publications

15	Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. *Science Translational Medicine*, **2017**, 9,	17.5	69
14	A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development. *MBio*, **2016**, 7,	7.8	96
13	The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. *Science Translational Medicine*, **2016**, 8, 330ra36	17.5	153
12	Dengue human infection models to advance dengue vaccine development. *Vaccine*, **2015**, 33, 7075-82	4.1	36
11	Dengue viruses cluster antigenically but not as discrete serotypes. *Science*, **2015**, 349, 1338-43	33.3	139
10	The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. *Journal of Virology*, **2015**, 89, 120-8	6.6	118
9	Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. *Vaccine*, **2013**, 31, 3347-52	4.1	29
8	A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. *Journal of Infectious Diseases*, **2013**, 207, 957-65	7	114
7	Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. *Vaccine*, **2011**, 29, 7242-50	4.1	86
6	Prospects for a dengue virus vaccine. *Nature Reviews Microbiology*, **2007**, 5, 518-28	22.2	434
5	The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. *Hum Vaccin*, **2006**, 2, 167-73		79
4	rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. *Hum Vaccin*, **2006**, 2, 255-60		80
3	Development of a live attenuated dengue virus vaccine using reverse genetics. *Viral Immunology*, **2006**, 19, 10-32	1.7	80
2	rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. *Journal of Infectious Diseases*, **2005**, 191, 710-8	7	112
1	Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. *BMC Infectious Diseases*, **2004**, 4, 39	4	54